17β-Hydroxysteroid dehydrogenase
type 2 (17β-HSD2)
converts the active steroid hormones estradiol, testosterone, and
5α-dihydrotestosterone into their weakly active forms estrone,
Δ4-androstene-3,17-dione, and 5α-androstane-3,17-dione,
respectively, thereby regulating cell- and tissue-specific steroid
action. As reduced levels of active steroids are associated with compromised
bone health and onset of osteoporosis, 17β-HSD2 is considered
a target for antiosteoporotic treatment. In this study, a pharmacophore
model based on 17β-HSD2 inhibitors was applied to a virtual
screening of various databases containing natural products in order
to discover new lead structures from nature. In total, 36 hit molecules
were selected for biological evaluation. Of these compounds, 12 inhibited
17β-HSD2 with nanomolar to low micromolar IC50 values.
The most potent compounds, nordihydroguaiaretic acid (1), IC50 0.38 ± 0.04 μM, (−)-dihydroguaiaretic
acid (4), IC50 0.94 ± 0.02 μM,
isoliquiritigenin (6), IC50 0.36 ± 0.08
μM, and ethyl vanillate (12), IC50 1.28
± 0.26 μM, showed 8-fold or higher selectivity over 17β-HSD1.
As some of the identified compounds belong to the same structural
class, structure–activity relationships were derived for these
molecules. Thus, this study describes new 17β-HSD2 inhibitors
from nature and provides insights into the binding pocket of 17β-HSD2,
offering a promising starting point for further research in this area.